Welcome to our dedicated page for Optinose SEC filings (Ticker: OPTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Optinose, Inc. (NASDAQ: OPTN) SEC filings page on Stock Titan is intended to organize the company’s regulatory disclosures in one place, helping investors understand how this specialty pharmaceutical issuer reports on its business. Optinose focuses on patients treated by ear, nose and throat (ENT) and allergy specialists and generates net product revenue primarily from sales of its drug-device combination product XHANCE. In its public financial reports, the company presents net product revenues, cost of product sales, research and development expenses, selling, general and administrative expenses, income or loss from operations, other income or expense, and net income or loss.
While specific SEC documents are not listed here, Optinose’s press releases reference audited and unaudited financial statements and related reports such as its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. These filings include details on classification of liabilities under its Amended and Restated Note Purchase Agreement and a going concern paragraph indicating substantial doubt about the company’s ability to continue as a going concern.
On Stock Titan, Optinose filings can be paired with AI-powered summaries that explain the key elements of lengthy reports, such as how net revenue from XHANCE has trended over time, how operating expenses are composed, and how balance sheet items like cash, total assets, liabilities, and stockholders’ deficit or equity have evolved. Investors can also use this page to monitor disclosures related to capital structure changes, including the 1-for-15 reverse stock split of Optinose’s common stock, and to follow narrative and risk factor discussions connected to the company’s agreement to be acquired by Paratek Pharmaceuticals, as described in its public communications.
Schedule 13G/A filing by Nantahala Capital Management, LLC and two individuals reporting zero beneficial ownership in OptiNose, Inc. The filing states that as of June 30, 2025, Nantahala and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 0 shares of OptiNose common stock (CUSIP 68404V209), representing 0.00% of the class. The filing identifies Nantahala as an investment adviser organized in Massachusetts and lists the reporting persons' business address in New Canaan, Connecticut. Signatures include Nantahala through its Chief Compliance Officer and both individual reporting persons, dated August 14, 2025.
OptiNose, Inc. filing discloses that Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon report beneficial ownership of 0 common shares (0.0%) of OptiNose common stock. The filing lists no sole or shared voting power and no sole or shared dispositive power for any reporting person.
The statement identifies Rosalind Advisors as an adviser and Salamon and Aharon as portfolio managers and includes a certification that the securities are held in the ordinary course of business and were not acquired to influence control; ownership is reported as 5% or less.